AnaptysBio (LTS:0HFQ) Receivables Turnover : 1.63 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is AnaptysBio Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. AnaptysBio's Revenue for the three months ended in Dec. 2024 was $43.11 Mil. AnaptysBio's average Accounts Receivable for the three months ended in Dec. 2024 was $26.48 Mil. Hence, AnaptysBio's Receivables Turnover for the three months ended in Dec. 2024 was 1.63.

AnaptysBio Receivables Turnover Historical Data

The historical data trend for AnaptysBio's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio Receivables Turnover Chart

AnaptysBio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Receivables Turnover

Get a 7-Day Free Trial

72.12

8.96

4.15

3.83

AnaptysBio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Receivables Turnover	Get a 7-Day Free Trial															1.78	1.03	1.36	2.83	1.63

Competitive Comparison of AnaptysBio's Receivables Turnover

For the Biotechnology subindustry, AnaptysBio's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AnaptysBio's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

AnaptysBio Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

AnaptysBio's Receivables Turnover for the fiscal year that ended in Dec. 2024 is calculated as

	Receivables Turnover (A: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2024 )	/ (	(Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )
=	91.28	/ (	(6.851	+	40.765)	/	2 )
=	91.28	/	23.808
=	3.83

AnaptysBio's Receivables Turnover for the quarter that ended in Dec. 2024 is calculated as

	Receivables Turnover (Q: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2024 )	/ (	(Accounts Receivable (Q: Sep. 2024 )	+	Accounts Receivable (Q: Dec. 2024 ))	/	count )
=	43.113	/ (	(12.195	+	40.765)	/	2 )
=	43.113	/	26.48
=	1.63

AnaptysBio (LTS:0HFQ) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

AnaptysBio Receivables Turnover Related Terms

Thank you for viewing the detailed overview of AnaptysBio's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

AnaptysBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (LTS:0HFQ) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

ANAB:USA AN6:Germany

Address

10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121

Website

https://www.anaptysbio.com

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

AnaptysBio Headlines

No Headlines